Takeda Pharmaceutical Company Limited (NYSE:TAK) received FDA approval for GAMMAGARD LIQUID ERC, a ready-to-use liquid IG therapy with low IgA content for primary immunodeficiency. It can be administered intravenously or subcutaneously, making treatment easier. Commercialization in the US is expected in 2026, with EU launch in 2027 as DEQSIGA.

Takeda Pharmaceutical (TAK) is a Japanese biopharmaceutical company focused on various therapeutic areas. While TAK shows investment potential, other AI stocks may offer greater upside. A report highlights an undervalued AI stock benefiting from tariffs and onshoring trends. For more on semiconductor and fintech stocks, visit Insider Monkey.

Read more at Yahoo Finance: Takeda Pharmaceutical (TAK) Gets GAMMAGARD LIQUID ERC Approved by FDA